Abstract:TRAF associated NF-κB activator (TANK) is adaptor protein which was identified as a negative regulator of TRAF-, TBK1- and IKKi-mediated signal transduction through its interaction with them. Besides its important roles in the regulation of immune response, it has been reported that TANK contributes to the development of autoimmune nephritis and osteoclastogenesis. However, its functions in cardiovascular diseases especially cardiac hypertrophy is largely unknown. In the present study, we interestingly observed that TNAK expression is increased by 240% in human hypertrophic cardiomyopathy(HCM)tissue and 320% in mouse hypertrophic heart after aortic banding (AB), indicating that TANK may be involved in the pathogenesis of this diseases. Subsequently, cardiac-specific TANK knockout (TANK-KO) and transgenic(TANK-TG)mice were generated and subjected to AB for 4 to 8 weeks. Our results demonstrated that TANK deficiency prevented against cardiac hypertrophy and fibrosis induced by pressure overload,as evidenced by that the cardiomyocytes enlargement and fibrosis formation was reduced by about 34% and 43% compared with WT mice, respectively. Conversely, TANK-TG mice showed an aggravated effect on cardiac hypertrophy in response to pressure overload with 36% and 47% increase of cardiomyocytes enlargement and fibrosis formation compared with non-transgenic mice. More importantly, in vitro experiments further revealed that TANK overexpression which was mediated by adenovirus in the cardiomyocytes dramatically increased the cell size and the expression of hypertrophic markers, whereas TANK knockdown had an opposite function. Mechanistically, we discovered that AKT signaling was activated (230%) in the hearts of TANK-TG mice, while being greatly reduced in TNAK-KO hearts after aortic banding. Moreover, blocking AKT/GSK3β signaling with a pharmacological AKT inhibitor reversed cardiac dysfunction of TANK-TG mice. Collectively, our data show that TNAK acts as a novel regulator of pathological cardiac hypertrophy and may be a promising therapeutic targets.

Research Progress of the Giant Scaffold Protein AHNAK in Associated Diseases

AHNAKs roles in physiology and malignant tumors

Research Progress in Gasdermin Family Proteins and Their Association with Diseases

The giant protein AHNAK involved in morphogenesis and laminin substrate adhesion of myelinating Schwann cells

Peptide Derived from AHNAK Inhibits Cell Migration and Proliferation in Hirschsprung's Disease by Targeting the ERK1/2 Pathway

The Obscure Potential of AHNAK2

AHNAK Suppresses Tumour Proliferation and Invasion by Targeting Multiple Pathways in Triple-Negative Breast Cancer

AHNAK Contributes to Hepatocellular Carcinoma Growth by Interacting with IGF-1R

Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition

AHNAK suppresses ovarian cancer progression through the Wnt/β-catenin signaling pathway

A scaffold protein, AHNAK1, is required for calcium signaling during T cell activation

Targeting AKAP79/150 in Human Disorders: An Emerging Opportunity for Future Therapies?

AHNAK2 Promotes Migration, Invasion, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cells via the TGF-β/Smad3 Pathway

Research progress of ankyrin repeat domain 1 protein: an updated review

Cardiac Function Modulation Depends on the A‐kinase Anchoring Protein Complex

The carboxyl-terminal region of ahnak provides a link between cardiac L-type Ca2+ channels and the actin-based cytoskeleton

The scaffold protein AXIN1: gene ontology, signal network, and physiological function

Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases

Abstract 026: Role of Tank in the Regulation of Pathological Cardiac Hypertrophy

AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma

AHNAK2 Regulates NF-κB/MMP-9 Signaling to Promote Pancreatic Cancer Progression